Pharma Mar, S.A. (PHMMF)

Market Cap	1.45B -19.4%
Revenue (ttm)	249.79M +15.5%
Net Income	64.12M +33.6%
EPS	3.56 +29.1%
Shares Out	n/a
PE Ratio	22.59
Forward PE	14.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	94.60
Previous Close	94.60
Day's Range	94.60 - 94.60
52-Week Range	77.41 - 110.40
Beta	0.43
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 27, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 505
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHMMF

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error